Table 2.
42-day and 28-day PCR-corrected and PCR-uncorrected efficacy according to antimalarial treatment in the intention-to-treat and per-protocol populations
| Artemether–lumefantrine | Arterolane–piperaquine–mefloquine | Arterolane–piperaquine |
Risk difference (95% CI); p value |
||
|---|---|---|---|---|---|
| Arterolane–piperaquine–mefloquine versus artemether–lumefantrine | Arterolane–piperaquine–mefloquine versus arterolane–piperaquine | ||||
| Efficacy at day 42 | |||||
| PCR-corrected in the intention-to-treat population | 69/72 (96%, 88 to 99) | 72/72 (100%, 95 to 100) | 73/73 (100%, 95 to 100) | 4 (0 to 9); 0·25 | 0 |
| PCR-uncorrected in the intention-to-treat population | 36/72 (50%, 38 to 62) | 56/72 (78%, 66 to 86) | 66/73 (90%, 81 to 96) | 28 (13 to 43); 0·0009 | −12 (−24 to −1); 0·043 |
| PCR-corrected in the per-protocol population | 35/36 (97%, 86 to 100) | 60/60 (100%, 94 to 100) | 65/65 (100%, 95 to 100) | 3 (−3 to 8); 0·38 | 0 |
| PCR-uncorrected in the per-protocol population | 32/65 (49%, 37 to 62) | 54/68 (79%, 68 to 88) | 62/66 (94%, 85 to 98) | 30 (15 to 46); 0·0003 | −15 (−26 to −3); 0·021 |
| Efficacy at day 28 | |||||
| PCR-corrected in the intention-to-treat population | 72/72 (100%, 95 to 100) | 72/72 (100%, 95 to 100) | 73/73 (100%, 95 to 100) | 0 | 0 |
| PCR-uncorrected in the intention-to-treat population | 48/72 (67%, 55 to 77) | 69/72 (96%, 88 to 99) | 70/73 (96%, 89 to 99) | 29 (17 to 41); <0·0001 | 0 (−7 to 6); 1·0 |
| PCR-corrected in the per-protocol population | 44/44 (100%, 92 to 100) | 67/67 (100%, 95 to 100) | 67/67 (100%, 95 to 100) | 0 | 0 |
| PCR-uncorrected in the per-protocol population | 42/65 (65%, 52 to 76) | 67/68 (99%, 92 to 100) | 66/66 (100%, 95 to 100) | 34 (22 to 46); <0·0001 | −2 (−4 to 1); 1·0 |
Data are n/N (%, 95% CI), unless otherwise specified. p values were calculated by use of two-sided Fisher's exact tests.